ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
Long-term remission and incidence of recurrence of neovascularization in intravitreal injection treated exudative age-related macular degeneration.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the long-term remission (LTR) rate, recurrence rate, and prognostic factors of extended remission and recurrence in macular neovascularization (MNV) eyes treated with aflibercept.
methodsThis was a retrospective cohort of treatment-naïve MNV eyes treated in Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan with intravitreal aflibercept between 2015 and 2023. Patients followed pro re nata (PRN) or Treat-and-Extend (T&E) protocols. Long-term remission (LTR) was defined as over 6 months of disease inactivity without injection. Binary logistic regression and Cox proportional hazard regression assessed associations with LTR and time to recurrence.
resultsOf 144 eyes, 68.75% achieved LTR after an average of 21.32 months after treatment, with no difference between PRN and T&E groups. Among LTR cases, 69.7% experienced recurrence after a median 15 months (range: 6 ~ 67). Firth multinomial logistic regression found younger age [OR, 0.898 (0.836 to 0.946; p = 0.032)], fewer injections per year [OR, 0 (0.000 to 0.001; p = 0.004)], polypoid choroidal vasculopathy (PCV) [OR, 6.170 (1.811 to 21.039; p = 0.033)], and retinal angiomatous proliferation (RAP) [OR, 24 450.658 (24 450.657 to 24 450.658; p < 0.001)] associated with LTR. Cox regression showed more yearly injections [HR, 7.621(0.376 to 0.972; p = 0.038)] led to earlier recurrence, while baseline subretinal fluid (SRF) [HR, 0.604 (0.376 to 0.972; p = 0.038)] delayed recurrence.
conclusionImplementing our exit strategies, 68.75% of eyes achieved LTR across the two injection protocols. Age, disease subtype, baseline anatomical features, and yearly injection numbers may predict sustained remission and a longer time to experience recurrence.
Indexed as
Identifiers
40608095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.